Anti-inflammatory disease-modifying treatment and short-term disability progression in SPMS
暂无分享,去创建一个
Pierre Grammond | Patrizia Sola | Murat Terzi | Cristina Ramo-Tello | Guillermo Izquierdo | Helmut Butzkueven | Maria Trojano | Dana Horakova | Alessandra Lugaresi | Tim Spelman | Tomas Kalincik | Franco Granella | Roberto Bergamaschi | Cavit Boz | Gerardo Iuliano | Daniele Spitaleri | M. Trojano | F. Grand'Maison | E. Havrdová | H. Butzkueven | R. Bergamaschi | G. Izquierdo | A. Lugaresi | C. Boz | C. Oreja-Guevara | P. Duquette | P. Sola | F. Granella | A. Prat | M. Girard | T. Spelman | D. Horáková | T. Kalincik | P. Grammond | V. van Pesch | G. Iuliano | V. Jokubaitis | E. Pucci | Marc Girard | Celia Oreja-Guevara | Pierre Duquette | Alexandre Prat | Eva Havrdova | J. Lorscheider | Johannes Lorscheider | D. Ferraro | M. Terzi | D. Spitaleri | C. Ramo-Tello | J. Lechner-Scott | François Grand'Maison | Eugenio Pucci | Jeanette Lechner-Scott | Vincent Van Pesch | Diana Ferraro | Vilija G. Jokubaitis | Johannes Lorscheider
[1] G. Cutter,et al. Treatment trials in progressive MS—current challenges and future directions , 2013, Nature Reviews Neurology.
[2] M. Rovaris,et al. Interferon beta for secondary progressive multiple sclerosis. , 2012, The Cochrane database of systematic reviews.
[3] Ludwig Kappos,et al. Placebo-controlled multicentre randomised trial of interferon β-1b in treatment of secondary progressive multiple sclerosis , 1998, The Lancet.
[4] D. Li,et al. Randomized controlled trial of interferon-beta-1a in secondary progressive MS , 2001, Neurology.
[5] Aaron E Miller,et al. Treatment of relapsing-remitting multiple sclerosis: current approaches and unmet needs. , 2012, Current opinion in neurology.
[6] Pierre Grammond,et al. Defining secondary progressive multiple sclerosis. , 2016, Brain : a journal of neurology.
[7] F. Paul,et al. Progressive multiple sclerosis: desperately seeking remedy. , 2013 .
[8] M. Rovaris,et al. Mitoxantrone for multiple sclerosis. , 2013, The Cochrane database of systematic reviews.
[9] J. Lechner-Scott,et al. Switch to natalizumab versus fingolimod in active relapsing–remitting multiple sclerosis , 2015, Annals of neurology.
[10] J. Lechner-Scott,et al. Comparative effectiveness of glatiramer acetate and interferon beta formulations in relapsing–remitting multiple sclerosis , 2015, Multiple sclerosis.
[11] R Core Team,et al. R: A language and environment for statistical computing. , 2014 .
[12] H. J. Hansen,et al. Multicentre, randomised, double blind, placebo controlled, phase III study of weekly, low dose, subcutaneous interferon beta-1a in secondary progressive multiple sclerosis , 2004, Journal of Neurology, Neurosurgery & Psychiatry.
[13] Pierre Grammond,et al. Highly active immunomodulatory therapy ameliorates accumulation of disability in moderately advanced and advanced multiple sclerosis , 2016, Journal of Neurology, Neurosurgery & Psychiatry.
[14] D. Ontaneda,et al. Clinical trials in progressive multiple sclerosis: lessons learned and future perspectives , 2015, The Lancet Neurology.
[15] P. Narayana,et al. Glatiramer acetate in primary progressive multiple sclerosis: Results of a multinational, multicenter, double‐blind, placebo‐controlled trial , 2007, Annals of neurology.
[16] Gary King,et al. MatchIt: Nonparametric Preprocessing for Parametric Causal Inference , 2011 .
[17] Randomized controlled trial of interferon- beta-1a in secondary progressive MS , 2001, Neurology.
[18] Uhc Campus. Interferon beta-1b in secondary progressive MS: Results from a 3-year controlled study , 2005 .
[19] N. Simonian,et al. “Summary measure” statistic for assessing the outcome of treatment trials in relapsing-remitting multiple sclerosis , 1998, Journal of neurology, neurosurgery, and psychiatry.
[20] B. Uitdehaag. Clinical outcome measures in multiple sclerosis. , 2014, Handbook of clinical neurology.
[21] H. Butzkueven,et al. Observational data: Understanding the real MS world , 2016, Multiple sclerosis.
[22] Jeffrey A. Cohen,et al. Benefit of interferon &bgr;-1a on MSFC progression in secondary progressive MS , 2002, Neurology.
[23] Pierre Grammond,et al. Defining reliable disability outcomes in multiple sclerosis. , 2015, Brain : a journal of neurology.
[25] J. Lechner-Scott,et al. Comparison of switch to fingolimod or interferon beta/glatiramer acetate in active multiple sclerosis. , 2015, JAMA neurology.
[26] H. Hartung,et al. Mitoxantrone in progressive multiple sclerosis: a placebo-controlled, double-blind, randomised, multicentre trial , 2002, The Lancet.
[27] M. Tsolaki,et al. Data quality evaluation for observational multiple sclerosis registries , 2017, Multiple sclerosis.